Lean-DM

Lean cohort

1. Men and women>18 years of age;

2. Normal body weight (18.5 ≤ BMI ≤25 kg/m2);

3. T2D patients can be on treatment with oral glucose lowering therapies, and if they are, they must have been on these treatments for at least 12 weeks prior to screening;

4. 6.5≤HBA1c≤10% at screening;

5. Agreement to maintain prior diet and exercise habits for the duration of the study.

Overweight cohort

1. Men and women>18 years of age;

2. Increased body weight (BMI >27 kg/m2);

3. T2D patients can be on treatment with oral glucose lowering therapies, and must have been on these treatments for at least 12 weeks prior to screening;

4. 6.5≤HBA1c≤10% at screening;

5. Agreement to maintain prior diet and exercise habits for the duration of the study.

1. Any type of diabetes other than T2D;

2. Past history of significant CAD;

3. Known HF;

4. Significant renal impairment (eGFR<30ml/min/m2);

5. Participation in a clinical trial of an investigational medicinal product (CTIMP) in the preceding 12 weeks;

6. Known hypersensitivity to dobutamine or gadolinium or any other contra-indications to MRI;

7. Participants with obesity where their girth exceeds the scanner bore;

8. History of pancreatitis;

9. Any history of liver disease;

10. Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);

11. Prior or current use of thiazolidinediones (aka PPAR-γ agonists), fibrates, GLP-1RA or insulin;

12. Patients that are pregnant (female participants only);

13. Inflammatory bowel disease

14. Diabetic gastroparesis